Company intelligence / Profile preview
Cardiogeni
San Francisco, California, United Statescardiogeni.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cardiogeni is an early-stage biotechnology company focused on developing innovative regenerative therapies for cardiovascular diseases. The company leverages a proprietary mRNA-based delivery platform designed to stimulate the growth of new blood vessels and repair damaged heart tissue following ischemic events. Their lead programs focus on the localized delivery of vascular endothelial growth factor (VEGF) to treat conditions such as myocardial infarction and chronic heart failure. By utilizing transient mRNA expression, Cardiogeni aims to provide a safer and more controlled alternative to traditional viral gene therapies for cardiac regeneration.
- Therapeutic areas
- Cardiovascular
- Modalities
- Gene therapymRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Cardiogeni.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardiogeni.